Business Wire

The “Cherry” Release of O-RAN Open Software Moves the O-RAN Ecosystem Closer to Deployment in Mobile Networks Around the Globe

Share

In December 2020, the O-RAN Software Community (OSC), working with the Linux Foundation, published its 3rd open software release within 18 months, dubbed “Cherry”.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005829/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

O-RAN Logical Architecture (Graphic: Business Wire)

Cherry moves the O-RAN ecosystem closer to commercial deployments in mobile networks around the globe. On top of new functions aligned with the latest O-RAN specifications, such as the E2, A1 and O1 interfaces, this release also features significant advancements in the end-to-end integration of O-RAN Architecture components to meet the needs of early adopters. In addition, new software projects in the area of Service Management and Orchestration (SMO) have been initiated to drive the development of auto-configuration and management of O-RAN elements.

The main use cases delivered in Cherry include:

  • Policy based Traffic Steering using the A1 and E2 interfaces
  • Automated Monitoring and Health check of selected components using the O1 interface
  • Configuration, Fault and Performance Management Services aligned with OAM models and specifications newly approved by O-RAN
  • Life Cycle Management Framework of rApps and xApps using SMO
  • O-DU Low and High pairwise testing in O-RAN Software Community lab
  • Simulators for testing and integration, such as E2, A1, Open Test Framework, and more

“It is gratifying to see the continued momentum of the OSC’s open-source O-RAN implementation,” said Jack Murray, co-chair of the OSC Technical Operating Committee (TOC) and Assistant Vice President of AT&T. “AT&T is proud to have continued its contributions to enable RAN AI/ML through the Near-Real Time RIC implementation, and to provide a platform for software testing and integration.”

“We are glad to see Cherry has made big progress by building on the base of Bronze,” said Chih-Lin I, the Co-Chair of O-RAN Technical Steering Committee. “It not only realizes more 3GPP-defined models, but also brings O-RAN defined interfaces including E2 and A1 closer to commercialization. More ML and AI technologies are implemented in the RIC, RICAPP and NRTRIC projects to push the traffic steering e2e use case forward, which makes it a more intelligent RAN. The newly created SMO project is also worth special mention for the quick momentum that it has gained in contributing to O-RAN automation and management within just 3 months.”

“Nokia continues to be very active in O-RAN and a major contributor to the O-RAN specifications,” said Pasi Toivanen, Head of Edge Cloud Platforms at Nokia. “With the Cherry Release, Nokia is contributing to the Near-Real-Time RIC and the E2 interface to advance RAN programmability, network openness, and the introduction of AI/ML intelligence to the network. The contributions also deliver increased robustness, more xApp framework capabilities and enhanced manageability of RIC platform and xApps.”

“Radisys continues to contribute actively to O-RAN standardization and open source development. In the Cherry release, Radisys enhanced O-DU L2 implementation to support UE attach, and integrated with PHY (O-DU Low) through the FAPI interface to enable end-to-end testing," said Ganesh Shenbagaraman, Head of Integrated Products and Ecosystems at Radisys.

“highstreet technologies substantially contributes to O1/OAM within both O-RAN and OSC,” said Alfons Mittermaier, Managing Director of highstreet technologies. “We expect the disaggregated O-RAN architecture to become a door opener for small and medium sized enterprises and will deploy the Cherry release in a 5G reference network in Berlin.”

“HCL has contributed to the O-RAN Software Community across different Work Groups starting with the Cherry Release,” said Ramesh Sriraman, the Head of Telecom Center of Excellence at HCL. “We Improved Near-Real-Time RIC platform CI/CD deployment, automation, performance & scale; introduced AI/ML intelligence to RAN network via xApps; and contributed the initial implementation of the O-RAN O1 interface in the O-DU. It is a great honor for HCL to develop together with the OSC team.”

To learn more about the O-RAN Software Community Cherry release please read this O-RAN Blog post, and to access the code, check out the O-RAN Software Community website.

The O-RAN Software Community continues to be open to any participants that want to get involved in the creation of software for future RAN – for more details please visit https://www.o-ran.org/software.

About O-RAN ALLIANCE

The O-RAN ALLIANCE is a world-wide community of more than 240 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.

For more information please visit www.o-ran.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye